Todos Medical has secured two Notices of Allowance from the United States Patent & Trademark Office (USPTO) for its Total Biochemical Infrared Analysis (TBIA) Fourier Transformed Infrared (FTIR) pan-cancer blood diagnostics platform, which uses artificial intelligence (AI).

The medical diagnostics company said that the notices were issued for patent applications entitled Infrared (IR) Spectroscopy System and Infrared Analysis of Benign Tumours.

Todos Medical already has CE marks secured for its TBIA blood diagnostic test for its use in breast cancer and colon cancer.

Todos Medical president and CEO Gerald Commissiong said: “The allowance of these two seminal pieces of intellectual property underlying the Company’s TBIA FTIR pan-cancer diagnosis platform, which we believe will ultimately outcompete the liquid biopsy platform for routine testing of asymptomatic and early-stage cancer patients, including tests such as Illumina’s Galleri.

“As we prepare to launch our Videssa breast cancer test in 2023, it will be very important to capture TBIA FTIR data from each patient tested with Videssa so we can continue to build the TBIA FTIR algorithm in order to gather sufficient data to submit to FDA.

“This platform will allow us to test for multiple cancers from the same blood sample because of the power of spectroscopy, as compared with more traditional antibody-based assays that make multiplexing challenging.”

According to the medical diagnostics company, the key allowed claim for the patent application for IR Spectroscopy System was around the system of collecting blood and getting FTIR spectrum from peripheral blood lymphocytes.

Todos Medical said that the system also has an output device designed to produce an output indicative of the existence of a solid tumour.

Recently, the company reported that its majority-owned joint venture 3CL Pharma had been granted a Notice of Allowance by the USPTO for its TolloTest.

Todos Medical developed TolloTest as a SARS-CoV-2 3CL protease diagnostic for detecting and quantifying the occurrence of 3CL protease in human tissue samples.